herceptin, lapatinib remain effective afterwards if TDM-1 no longer effective
Good to know!
Ann Oncol. 2011 Apr 29. [Epub ahead of print] Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Olson EM, Lin NU, Dipiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Source Department of Medical Oncology. Abstract BACKGROUND: Women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) can respond to multiple lines of anti-HER2 therapy. It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1 (T-DM1). PATIENTS AND METHODS: We retrospectively identified HER2-positive MBC patients treated with T-DM1 and characterized outcomes during subsequent lines of anti-HER2 therapy. Response was determined by a blinded radiology review. Time-dependent analyses were carried out using Kaplan-Meier estimates. RESULTS: We identified 23 patients treated with single-agent T-DM1 and report on the 20 patients who discontinued protocol therapy. All patients received trastuzumab-based metastatic therapy before initiation of T-DM1 [median 7 regimens (range 3-14)]. Of these 20 patients, 75% (15 of 20) received further therapy with or without anti-HER2 agents after discontinuing T-DM1. Partial response to either first- or second-subsequent line(s) of therapy was seen in 5 of 15 (33%) treated patients, including 33% (4 of 12) who received a regimen containing trastuzumab and/or lapatinib. Median durations of therapy to first- and second-subsequent regimens after T-DM1 were 5.5 and 6.4 months, respectively. CONCLUSIONS: In heavily pretreated HER2-positive MBC patients, prior exposure to T-DM1 does not exhaust the potential benefit of ongoing anti-HER2 therapy with trastuzumab- and/or lapatinib-based regimens. PMID: 21531783 [P |
Re: herceptin, lapatinib remain effective afterwards if TDM-1 no longer effective
Thanks Lani. Very interesting. As usual!
It would also be interesting to know how long the 23 took TDM1 and why the treatment was discontinued for 20. I figure progression? 20/23? I hope I got it wrong. "Median durations of therapy to first- and second-subsequent regimens after T-DM1 were 5.5 and 6.4 months, respectively". Every progress is good to take I first hope that TDM1 will be a breakthrough for many. |
Re: herceptin, lapatinib remain effective afterwards if TDM-1 no longer effective
Lani,
This post came right on time! Kim |
Re: herceptin, lapatinib remain effective afterwards if TDM-1 no longer effective
Probably another case of a SUBGROUP that has sensitivity to the targeted drugs having a better outcome.
|
Re: herceptin, lapatinib remain effective afterwards if TDM-1 no longer effective
Yes. Good to know !!!!!!!!
|
All times are GMT -7. The time now is 02:37 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021